TY - CHAP M1 - Book, Section TI - Acute Myeloid Leukemia A1 - Heuser, Michael A1 - Thol, Felicitas A2 - Murray, Michael F. A2 - Babyatsky, Mark W. A2 - Giovanni, Monica A. A2 - Alkuraya, Fowzan S. A2 - Stewart, Douglas R. PY - 2014 T2 - Clinical Genomics: Practical Applications in Adult Patient Care AB - Disease summary:Acute myeloid leukemia (AML) is a malignant disease originating from a hematopoietic cell that has acquired self-renewal properties. Hundreds of genetic aberrations have been described in AML cells, and recent evidence suggests that on average 13 genetic aberrations are present in AML cells.Patients usually present with signs of anemia, infection, or bleeding.The diagnosis is made if greater than or equal to 20 myeloid blasts are present in peripheral blood or bone marrow.Conventional cytogenetics and molecular screening for fusion proteins PML-RARĪ±, RUNX1-RUNX1T1, CBFB-MYH11, and for mutations of NPM1, CEBPA, and FLT3 should be obtained at diagnosis.Intensive chemotherapy should be given to all eligible patients consisting of cytarabine and an anthracycline.Consolidation treatment consists of high-dose cytarabine or allogeneic hematopoietic stem cell transplantation depending on prognostic factors.Acute promyelocytic leukemia (APL) is treated differently than other AML patients (including all-trans retinoic acid [ATRA] and an anthracycline) and has a good prognosis. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1102700048 ER -